Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: Effects on markers of inflammation and innate immunity in cervicovaginal fluid

Deborah J. Anderson, D'Nyce L. Williams, Susan A. Ballagh, Kurt Barnhart, Mitchell D Creinin, Daniel R. Newman, Frederick P. Bowman, Joseph A. Politch, Ann C. Duerr, Denise J. Jamieson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. Method of study: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex® (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14days in combination with one of the two acid-buffering microbicide gels [ACIDFORM™ (Instead Inc., La Jolla, CA, USA) or BufferGel™ (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly®; Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. Results: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. Conclusions: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalAmerican Journal of Reproductive Immunology
Volume61
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Lubricants
Anti-Infective Agents
Diaphragm
Innate Immunity
Gels
Inflammation
Safety
Secretory Leukocyte Peptidase Inhibitor
Placebos
Therapeutic Irrigation
Foams and Jellies Vaginal Creams
Inflammation Mediators
Baltimore
Enzyme-Linked Immunosorbent Assay
Acids

Keywords

  • Cytokines
  • Diaphragm
  • Human immunodeficiency virus
  • Inflammation
  • Innate immunity
  • Microbicides

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels : Effects on markers of inflammation and innate immunity in cervicovaginal fluid. / Anderson, Deborah J.; Williams, D'Nyce L.; Ballagh, Susan A.; Barnhart, Kurt; Creinin, Mitchell D; Newman, Daniel R.; Bowman, Frederick P.; Politch, Joseph A.; Duerr, Ann C.; Jamieson, Denise J.

In: American Journal of Reproductive Immunology, Vol. 61, No. 2, 2009, p. 121-129.

Research output: Contribution to journalArticle

Anderson, Deborah J. ; Williams, D'Nyce L. ; Ballagh, Susan A. ; Barnhart, Kurt ; Creinin, Mitchell D ; Newman, Daniel R. ; Bowman, Frederick P. ; Politch, Joseph A. ; Duerr, Ann C. ; Jamieson, Denise J. / Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels : Effects on markers of inflammation and innate immunity in cervicovaginal fluid. In: American Journal of Reproductive Immunology. 2009 ; Vol. 61, No. 2. pp. 121-129.
@article{17648d7d776f43c6aba94da5dfe5b287,
title = "Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: Effects on markers of inflammation and innate immunity in cervicovaginal fluid",
abstract = "Objective: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. Method of study: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex{\circledR} (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14days in combination with one of the two acid-buffering microbicide gels [ACIDFORM™ (Instead Inc., La Jolla, CA, USA) or BufferGel™ (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly{\circledR}; Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. Results: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. Conclusions: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.",
keywords = "Cytokines, Diaphragm, Human immunodeficiency virus, Inflammation, Innate immunity, Microbicides",
author = "Anderson, {Deborah J.} and Williams, {D'Nyce L.} and Ballagh, {Susan A.} and Kurt Barnhart and Creinin, {Mitchell D} and Newman, {Daniel R.} and Bowman, {Frederick P.} and Politch, {Joseph A.} and Duerr, {Ann C.} and Jamieson, {Denise J.}",
year = "2009",
doi = "10.1111/j.1600-0897.2008.00670.x",
language = "English (US)",
volume = "61",
pages = "121--129",
journal = "American Journal of Reproductive Immunology",
issn = "8755-8920",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels

T2 - Effects on markers of inflammation and innate immunity in cervicovaginal fluid

AU - Anderson, Deborah J.

AU - Williams, D'Nyce L.

AU - Ballagh, Susan A.

AU - Barnhart, Kurt

AU - Creinin, Mitchell D

AU - Newman, Daniel R.

AU - Bowman, Frederick P.

AU - Politch, Joseph A.

AU - Duerr, Ann C.

AU - Jamieson, Denise J.

PY - 2009

Y1 - 2009

N2 - Objective: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. Method of study: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex® (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14days in combination with one of the two acid-buffering microbicide gels [ACIDFORM™ (Instead Inc., La Jolla, CA, USA) or BufferGel™ (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly®; Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. Results: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. Conclusions: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.

AB - Objective: Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. Method of study: Eighty-one non-pregnant women were randomized into three groups and instructed to use Milex® (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14days in combination with one of the two acid-buffering microbicide gels [ACIDFORM™ (Instead Inc., La Jolla, CA, USA) or BufferGel™ (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K-Y Jelly®; Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio-Plex or ELISA. Results: Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. Conclusions: Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.

KW - Cytokines

KW - Diaphragm

KW - Human immunodeficiency virus

KW - Inflammation

KW - Innate immunity

KW - Microbicides

UR - http://www.scopus.com/inward/record.url?scp=58249126975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249126975&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0897.2008.00670.x

DO - 10.1111/j.1600-0897.2008.00670.x

M3 - Article

C2 - 19143675

AN - SCOPUS:58249126975

VL - 61

SP - 121

EP - 129

JO - American Journal of Reproductive Immunology

JF - American Journal of Reproductive Immunology

SN - 8755-8920

IS - 2

ER -